After Watching Gilead Sciences And Roche Dive Deeper Into Tigit Immunotherapies, Novartis Is Heading Straight For The Senior Class. The Swiss Pharma Is Getting In On The Game Via A Blockbuster Deal With Beigene, Which Could Ultimately Net $1 Billion For A Late-Stage Asset.Novartis Will Pay $300 Million Upfront And Could Shell Out Up To $700 Million Down The Line In Milestones For The Tigit Inhibitor Ociperlimab If An Option Is Exercised Before 2023, According To A Monday Statement. This Is Novartis
